4baseCare Raises $15M for Global Genomics and AI Expansion

Precision oncology innovator 4baseCare has successfully closed a Series B funding round, securing ₹128 crore (approximately $15.36 million USD). This significant capital injection is earmarked for the global expansion of its hospital-integrated genomics laboratory network and the enhancement of its artificial intelligence-driven precision oncology platform, OncoTwin. The funding round saw robust participation from key investors, underscoring confidence in the company's trajectory within the rapidly evolving cancer care sector.

The investment was co-led by prominent figures Ashish Kacholia and Lashit Sanghvi, with continued support from existing investor Yali Capital. An additional ₹38 crore was contributed by growX Ventures and technology giant Infosys, signaling a strong belief in 4baseCare's technological advancements and market potential. This infusion of capital positions 4baseCare to accelerate its strategic growth initiatives over the next 12 to 18 months.

Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has established itself by integrating advanced genomics, sophisticated bioinformatics, and cutting-edge AI to deliver personalized cancer treatment strategies. The company's flagship platform, OncoTwin, functions as an AI-powered clinical decision support system. It continuously refines its insights by analyzing real-world clinico-genomic data, offering oncologists enhanced tools for patient management and therapeutic selection.

The strategic expansion plan targets key international markets, including the Middle East, Southeast Asia, Latin America, and Central Asia, alongside strengthening its presence within India. This global push is supported by the recent achievement of CAP accreditation for its Dubai genomics laboratory in March 2025, a critical step in establishing international quality benchmarks and operational readiness.

Financially, 4baseCare demonstrated strong performance, concluding fiscal year 2025 with revenues exceeding ₹35 crore. The company has set an ambitious target to reach ₹100 crore in revenue within the next 12 to 18 months, a testament to its scalable business model and the increasing demand for precision oncology solutions.

The precision oncology market is experiencing substantial growth, driven by advancements in genomic sequencing technology and a deeper understanding of cancer's molecular underpinnings. Industry reports suggest the global precision oncology market could reach tens of billions of dollars in the coming years, with AI playing an increasingly pivotal role in data interpretation and treatment optimization. 4baseCare's focus on integrating AI with robust genomic data positions it favorably within this expanding market, offering a competitive edge in delivering more effective and personalized cancer care.